CT-111 (Chantibody Therapeutics)

N/A

Report date: 2025/07/08 14:51:49
First In Class

Base Information

Drug NameCT-111 (Chantibody Therapeutics)
Drug Alias NameCT-111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionAnti-PD-1Anti-CTLA4Anti-Vascular endothelial growth factor
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4Vascular endothelial growth factor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChantibody Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Cell Therapy Group Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A